Table 1 Patient and clinical characteristics with PET/CT findings
From: A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making
Sex | Age (years) | Scan delaya (days) | Underlying disorder liver | BCLC stage | Previous therapy | Degree of differentiation at histopathology | Reason for dual-tracer examination | Critical finding | 18F-FDG | 11C-CH | Other findings | Follow-up therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
M | 49 | 2 | NASH | B | MWA | N/A | Suspect CT/MRI | Recurrence ablation site, mediastinal lymph node | + | − | Both: mHCC m. adductor longus | Palliative with chemotherapy |
F | 71 | 0 | Steatosis | C | MWA, Resection | Poorly | Rise of tumour marker | Recurrence ablation site, precaval lymph node | + | + | CH: needle tract recurrence, prostate carcinoma | BSC |
M | 72 | 1 | NASH | 0 | SIRT | Poorly | Suspect CT/MRI | Retrocaval lymph node | + | + | Immunotherapy | |
M | 77 | 0 | None | B | Poorly | Suspect CT/MRI | HCC liver right lobe and portocaval lymph node | + | + | FDG: liver lymph node CH: HCC S1 | Start systemic immunotherapy | |
F | 64 | 0 | NASH | B | MWA | Moderately | Suspect CT/MRI | mHCC Th6 | + | + | Radiotherapy | |
F | 74 | 3 | Cirrhosis (HBV) | A | Moderately | Rise of tumour marker | Growth known HCC S5/6 | − | + | Surgical partial liver resection | ||
F | 65 | 0 | Cirrhosis (Alcohol) | B | Well | Suspect CT/MRI | Bilateral lung carcinoma | + | + | Surgical partial lung resection | ||
F | 75 | 0 | Fibrosis | B | Resection | Well | Rise of tumour marker | HCC S1 | + | + | TACE | |
F | 39 | 12 | None | B | Well | Suspect CT/MRI | Multifocal HCC liver right lobe | + | + | OLT | ||
M | 75 | 12 | NASH | C | MWA | Well | Suspect CT/MRI | Needle tract recurrence after ablation | − | + | CH: 5th costovertebral junction | BSC |
M | 74 | 0 | Cirrhosis (Alcohol) | B | TACE | N/A | Suspect CT | HCC recurrence | − | − | SIRT | |
M | 66 | 0 | NASH | A | MWA | N/A | Suspect CT/MRI | Lymph node lesser omentum and a. hepatica communis | − | + | FDG: mHCC ablation site S4/5 | BSC |
M | 67 | 0 | Cirrhosis (Alcohol) | A | MWA | N/A | Rise of tumour marker | mHCC S1, HCC recurrence ablation site S2/3 | + | + | FDG: tumour thrombus v. porta | Palliative with sorafenib |
M | 81 | 1 | Cirrhosis (Hemochromatosis) | A | SIRT, MWA | N/A | Suspect CT/MRI | Thoracic lymph nodes | + | + | FDG: recurrence ablation site | Palliative with sorafenib |
M | 60 | 0 | Cirrhosis (Alcohol) | A | N/A | Suspect CT/MRI | Known HCC S7/8 | + | + | SIRT | ||
F | 76 | 0 | Cirrhosis (Alcohol) | C | N/A | Suspect CT/MRI. Rise of tumour marker | Known HCC S7/8 | + | + | SIRT | ||
M | 53 | 3 | Cirrhosis (Alcohol) | A | MWA, Resection | N/A | Rise of tumour marker | mHCC pararectal fat | − | + | Surgical local resection | |
M | 57 | 0 | NASH | A | N/A | Rise of tumour marker | mHCC liver subcapsular S8 | − | + | MWA | ||
F | 62 | 18 | Cirrhosis (Alcohol) | 0 | MWA | N/A | Rise of tumour marker | HCC S7/8 | + | − | MWA |